In one clinical study, the adoptive transfer of ex vivo expanded tumor infiltrating lymphocytes transduced to secrete IL-12 under the control of an NFAT-IL-2 minimal promoter induced significant toxicities attributed to high serum IL-12 levels in patients with melanoma (49). Here, IL2 is linked to neoplasm.